Use of thiazolidinediones in HIV-infected patients: What have we learned?

Journal of Infectious Diseases

Volumn 195, Issue 12, 2007, Pages 1731-1733

  Grinspoon, Steven ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RAMIPRIL; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NOTE; OBESITY; PRIORITY JOURNAL;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; DIABETES MELLITUS, TYPE 2; HIV INFECTIONS; HUMANS; THIAZOLIDINEDIONES;

EID: 34249896151     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518008     Document Type: Note

References (11)

1. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004; 140:786-94.
2. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist to hip ratio. AIDS 2007; 21:47-57.
3. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143:337-46.
4. Maachi M, Slama L, Lanoy E, et al. Effects of pioglitazone on limb fat and circulating adipokines in HIV-related lipodystrophy (abstract 23]. In: Program and abstracts of 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (San Francisco). London: International Medical Press, 2006.
5. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8:199-207.
6. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004; 363:429-38.
7. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007; 195:1754-61 (in this issue).
8. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 2004; 140:786-94.
9. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31:163-70.
10. Investigators DT, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-105.
11. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472-7.